Did chloroquine really fail a COVID-19 study—or was the trial design to blame?

News recently emerged that hydroxychloroquine—an anti-malaria drug highlighted by President Donald Trump as a promising coronavirus therapy—disappointed in a China clinical trial on mild COVID-19 patients. But a careful examination of the study reveals a more complicated situation.

Leave a Reply

Your email address will not be published. Required fields are marked *